Tyra Biosciences — Third Quarter 2026 Earnings Summary

Tyra Biosciences reported initial Phase 2 results for its oral FGFR3-selective inhibitor dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer, showing a 79% overall response rate at the 60 mg dose. The company completed a $400 million public offering in September 2026, bringing its total cash, cash equivalents, and marketable securities to $700.5 million as of September 30, 2026, which supports operations through 2030. During the third quarter of 2026, research and development expenses increased to $43.1 million, driven by ongoing clinical trials for dabogratinib across bladder cancer, upper tract urothelial carcinoma, and achondroplasia indications.